「and n」の検索結果
99件：61～65件目を表示
-
t M22 IPL Model is indicated for improvement of symptoms of Dry Eye Disease due to MGD (Meibomian Gland Dysfunction ), and was previously approved by the Ministry of Health, Labor and Welfare in Japan...
https://www.senju.co.jp/sites/default/files/content_news/2023-11/ENG__20231101_0.pdf -
t M22 IPL Model is indicated for improvement of symptoms of Dry Eye Disease due to MGD (Meibomian Gland Dysfunction ), and was previously approved by the Ministry of Health, Labor and Welfare in Japan...
https://www.senju.co.jp/sites/default/files/content_news/2023-11/ENG__20231101.pdf -
CEO Message | About Senju | SENJU Pharmaceutical
ablished in 1947, we have been making efforts for more than 70 years to develop excellent medicines and services focusing on the ophthalmology field through our unique ideas and R&D capabilities.T...
http://www.senju.co.jp/english/about/message.html -
for the treatment of Dry Eye Disease The Clinical Trials use a novel compound discovered by Mochida and licensed to Senju Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shu...
https://www.senju.co.jp/sites/default/files/content_news/2023-03/ENG_20230322_0.pdf -
for the treatment of Dry Eye Disease The Clinical Trials use a novel compound discovered by Mochida and licensed to Senju Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shu...
https://www.senju.co.jp/sites/default/files/content_news/2023-03/ENG_20230322.pdf